RxDoctor Payments Data

Usha Rao, MD

Critical Care Medicine · Austin, TXNPI 1952627010

Payments from drug & device makers

$1,565in general payments, 2019–2025

Across 68 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$410
  • Boehringer Ingelheim$302
  • Sanofi$205
  • AstraZeneca$175
  • Takeda Pharmaceuticals U.S.A., Inc.$81
  • United Therapeutics Corporation$64
  • plus $329 from 8 others

What the payments were for

  • Food & beverage$1,565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,565 in reported general payments places this provider in the 65th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$240,799
Medicare patients
711
Services billed
2,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter129$119,722
Spiriva RespimatTiotropium Bromide53$34,178
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$14,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$11,281
Advair HfaFluticasone Propion/Salmeterol17$10,621
SymbicortBudesonide/Formoterol Fumarate30$9,455
Arnuity ElliptaFluticasone Furoate28$7,130
Breo ElliptaFluticasone/Vilanterol12$6,202
BreynaBudesonide/Formoterol Fumarate11$4,128
Albuterol Sulfate HfaAlbuterol Sulfate110$3,360
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$3,219
Advair DiskusFluticasone Propion/Salmeterol14$3,192
Wixela InhubFluticasone Propion/Salmeterol17$2,285
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,169
Ventolin HfaAlbuterol Sulfate12$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta$410$133,054169 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$302$48,88967 claims
AstraZenecaBreztri Aerosphere, Symbicort$175$20,73542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →